Gastric Cancer (Metastatic) | Decision Base | US/EU5 | 2014

Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity

The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai’s Herceptin) in 2010 transformed the treatment algorithm for metastatic gastric cancer, segregating the population into those patients with HER2-positive disease (HER2 overexpressers) and therefore eligible for trastuzumab treatment, and those deemed HER2-negative. Despite the entrance of Herceptin, the outlook for patients with metastatic gastric cancer is bleak, notably for those with HER2-negative disease. Several emerging therapies including agents from novel drug classes are in development for metastatic gastric cancer; and owing to the high levels of unmet need, significant clinical and commercial opportunity exists for therapies that can provide greater survival benefits than current standards of care.

Login to access report